New research from St. Jude Children's Research Hospital and colleagues has found that disrupting Asxl1, a gene in T cells, improved sensitivity to a type of immunotherapy called immune checkpoint ...

Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2024 / 10 / 241010210022.htm ...

The study, published in the Proceedings of the National Academy of Sciences, reveals how a mutated gene called ASXL1 is involved in a disease called clonal hematopoiesis, a precursor to malignant ...

In the new study, mutating the ASXL1 gene spelled disaster for blood cells. Without heterochromatin working properly, hematopoietic stem cells never matured into normal blood cell lineages, ...

Disrupting Asxl1 gene prevents T-cell exhaustion, improving immunotherapy Scientists at St. Jude Children’s Research Hospital and colleagues found that disrupting the Asxl1 gene improves tumor ...

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall ...

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in ...

Recently, an article in Science by Dr. Caitlin C. Zebley and others demonstrated that blocking a specific gene, known as Asxl1, improves T cell function and enhances a traditional immunotherapeutic ...

The data are featured in a presentation, entitled “In vitro efficacy of CDK9 inhibitor tambiciclib (SLS009) in ASXL1 mutated colorectal cancer cell lines” at the 2025 American Society of ...

SELLAS Life Sciences Group, Inc. - The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market ...

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall ...

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall ...